Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


6 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

Medical Cannabis, watch list of pot-related stocks
nipper
post Posted: May 24 2020, 10:57 AM
  Quote Post


Posts: 7,100
Thanks: 2437


Tim Boreham banging the drum on LGP
QUOTE
By Tim Boreham | More Articles by Tim Boreham
With dozens of medicinal cannabis plays now listed on the ASX and with many pretenders along for the ride, the serious exponents need to offer investors more than opaque promises about exploiting the healing herb.

This is ever more the case given the so-called 'green gold' is at risk of becoming a commoditised market especially in jurisdictions such as the US where recreational pot is widely legalised.

So how do the genuine players stand out above the canopy of chancers?

Little Green Pharma (ASX:LGP) has some genuine pioneering notches on its belt. The Perth-based outfit was the first to produce a home-grown medicinal cannabis product for patient use (in August 2018) and it was also the first to export when it became legal to do so.

"Even today we are the only local producer among the 130 products available," says LGP founder and CEO Fleta Solomon. "There are lots of licences issued and a lot of people growing, but no-one has actually produced the finished medicines."

LGP is also generating meaningful revenue: a unicorn-type rarity in the sector. LGP can also claim another quirky milestone: it was the last stock to list in the pre COVID-19 bull market, with its February 20 ASX debut sneaking in ahead of the record peak the next day.

"People have expressed sympathy that we listed when we did," says Solomon. "But I say it was amazing because if we didn't list then we may never have listed. "We were so fortunate we got the window we did."

Solomon founded LGP in 2016, tapping her entrepreneurial skills honed from building up (and then selling) a workplace health outfit. Along the way LGP acquired precision drug dosing technology from an elderly inventor who was keen to retire.

Under its vertically-integrated model, LGP grows the cannabis hydroponically at its secret licensed facility in WA's south west. The plant material is processed at a third party facility, albeit with help from LGP staff using their equipment.

Currently, the company produces four variants of bottled oils containing various ratios of CBD (cannabidiol) and THC (tetrahydrocannabinol).

CBD is one of approximately 140 cannabinoids which has renowned therapeutic properties dating back thousands of years. THC is the famed intoxicating cannabis component, but also the requisite component to treat conditions such as pain and anxiety.

LGP's operations have all the requisite licences and its manufacturing partner is GMP (Good Manufacturing Practice) certified which enables the company to export to countries within the European Union. Only a handful of other providers are able to do so.

This month, the company received a manufacturing permit from the federal Office of Drug Control (ODC) which allows the company to perform extraction at its own processing facility onsite.

The $10 million raised in LGP's IPO will fund this facility and the company is currently waiting for its expanded ODC cultivation and production permit for its expanded growing facility which will produce enough material for 110,000 bottles a year (compared with 15,000 currently).

In the first six months to 31 December 2019, LGP recorded revenue of $716,000, up 188 per cent on the 12 months to 30 June 2019. The March quarterly statement the first financial results post listing showed receipts of $630,000 and operating cash outflows of $2.23 million.

The number of patients treated with LGP's therapies swelled to 3,175 growth of 1,119 new patients during the quarter.
In the month of March the company sold a record 1,580 of the 50 millilitre bottles, taking the accrued bottles sold to more than 10,450.

The backdrop to the Little Green Pharma story is the gradual acceptance of medicinal cannabis, which is legal in Australia but heavily regulated. Currently, the Therapeutic Goods Administration has approved only one cannabis therapy (Sativex, for multiple sclerosis spasticity). Otherwise, patients need to access the medicine via the regulator's Special Access Scheme, or via a network of authorised prescribers.

While it's up to the doctors to determine the best treatment, "approved indications" include anxiety, cancer-induced nausea and vomiting (CINV), post-traumatic stress disorder (PTSD), epilepsy, insomnia, and wasting.

Solomon says LGP's current products are similar to those that have been around for thousands of years. "We deliberately made it so, because the extensive real-world evidence that exists about how these oils are used makes it easier for doctors to prescribe." She says while the current products are important for building revenue, "down the track the differentiator for us is how the medicines are delivered."

In an exclusive partnership with Curtin University the company is working on ARISE, "a precision dosing methodology that could potentially make cannabis ingredients more bioavailable for the human body."

In the meantime, offshore markets beckon for LGP, via distribution agreements with Germany's CC Pharma and DEMECAN and Astral Health in Britain.

The company recently dispatched Australia's first medicinal cannabis export winning the praise of federal health minister Greg Hunt who is advocating Australian medicinal cannabis as a new export sector. This shipment was sent to Astral Health under a five-year contract which involves supplying product to the fast emerging UK medicinal cannabis market, which adheres to a similar regulatory framework as Australia's. Germany is especially appealing because while cannabis cultivation has only recently been legalised there, it's one of the world's biggest medicinal cannabis markets and prescriptions are generally rebated by health insurance companies.

Despite LGP's progress, the stock remains below the 45c a share IPO price but Solomon says the company's performance should take care of the valuation. "The market has taken a hit but we don't focus on that," she says. "We just know what we are doing and we know we have some really great news coming out."

The company has no debt, $6 million in cash and increasing sales month on month which provides a strong business case.

Solomon says it's rare to come across a business that presents both a commercial opportunity and the ability to make a
social impact. "By that I mean changing the life of patients," she says. "That's the reason the team at LGP gets out of bed every day."




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Mar 4 2020, 01:35 AM
  Quote Post


Posts: 7,100
Thanks: 2437


The medicinal cannabis industry has suffered a significant setback, with stock values plummeting as the product takes longer than expected to get to market.
QUOTE
Key points:
  • The industry is experiencing a correction, with people who sought a quick profit from the pot boom now feeling the pinch
  • Some companies have lost 50 to 80 per cent of their stockmarket value in the past year
  • Insiders say the industry's major bottleneck is being able to turn an illegal recreational substance into a pharmaceutical-grade drug


.https://www.abc.net.au/news/2020-03-03/medicinal-cannabis-shares-takes-hit-as-market-reality-sets-in/12012010?section=business



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 14 2020, 11:36 AM
  Quote Post


Posts: 7,100
Thanks: 2437


And another one, likely IPO in Feb
Little Green Pharma Ltd

some waffle at: https://smallcaps.com.au/little-green-pharm...nnabis-exports/



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jan 6 2020, 10:44 AM
  Quote Post


Posts: 7,100
Thanks: 2437


Here's an allied stock. Due to list Jan 2020
QUOTE
Emerald Clinics Limited EMD is an Australian incorporated company that operates a network of specialist medical clinics and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients.

Emerald is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emerald uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of cannabinoid-based medicines.

Emerald has established four medical centres in Australia including one site each in West Leederville WA, Woolloomooloo NSW, Tintenbar NSW and Richmond VIC. Additional Clinics are planned across Australia within the next 12 months. Emerald is also considering the viability of expanding its operations to the United Kingdom
- could be an interesting niche player with growth prospects (and hopefully high margins)




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 26 2019, 07:22 AM
  Quote Post


Posts: 7,100
Thanks: 2437


QUOTE
Industrial hemp and medicinal cannabis business Elixinol Global is now down 90 per since April 2019 when shares hit $5.93 on a valuation around $740 million.

The stock changed hands for just 51¢ this morning as problems mount up globally for the company. In the US it's facing a potential class action lawsuit alleging that it mislabelled its products as dietary supplements, while it also admitted Elixinol Japan had sold non-compliant hemp-derived products.

For the nine months to September 30, it posted an operating cash loss of $11.4 million on sales of $40.7 million, with $34.3 million in cash on hand. The former market darling is forecasting estimated cash outflows (before sales) of $24.2 million over the quarter to 31 Dec.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 21 2019, 06:43 AM
  Quote Post


Posts: 7,100
Thanks: 2437


The Psychedelic Renaissance

... a fair synopsis (although a bit foggy), and wishful thinking by someone

https://www.sharecafe.com.au/2019/12/20/a-p...ic-renaissance/

but as for this!!
QUOTE
Many microdosers come from the San Francisco area with the typical profile being an “übersmart twentysomething” curious to see whether microdosing will help him or her work through technical problems and become more innovative




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 

Featured Stock Stories





nipper
post Posted: Nov 25 2019, 07:44 PM
  Quote Post


Posts: 7,100
Thanks: 2437


QUOTE
Cann Group Ltd (ASX: CAN): The cannabis company’s shares are currently the worst performers on the All Ordinaries on Monday afternoon. At one stage they were down by 33% to 49 cents. They have since narrowed this decline slightly, but are still down 27% to 53.5 cents at the time of writing.
Why is the Cann Group share price crashing lower?
Investors appear to be selling Cann Group’s shares today after looking over the production plans it announced last week. Previously, the company was planning to complete the Mildura facility in a single stage development. This would give it a total capacity of 70,000 kgs of cannabis flower at an estimated project cost of $184 million. This was expected to generate annual revenues of approximately $220 million to $280 million

However, in response to weaker than expected demand and an oversupply of cannabis, management intends to split its construction into three stages. It estimates that first stage production will be around 25,000 kgs. And while management hasn’t updated its revenue forecast yet, I suspect the market is anticipating a sharp downgrade. Especially given the abundance of cannabis flower and the limited use that its offtake partner, Aurora Cannabis, has for it at present.
....
It isn’t all doom and gloom in the cannabis industry on Monday. Both AusCann Group Holdings Ltd (ASX: AC8) and Botanix Pharmaceuticals Ltd (ASX: BOT) are up 4.5% following updates this morning.

The AusCann share price is up after appointing TGA-licensed Aspen Pharmacare Australia to provide packaging for its medicinal cannabis pharmaceutical products.

Whereas the Botanix share price is up after following a US DEA announcement. It advised Botanix’s partner Purisys, that its synthetic cannabidiol product is no longer scheduled as a controlled substance. Botanix Executive Chairman, Vince Ippolito, believes this change will make a major difference to the speed of developing its products and greatly reduces the risks and costs of clinical development..

Motley Fool



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
Nopoo
post Posted: Jan 29 2019, 01:55 PM
  Quote Post


Posts: 147
Thanks: 6


In Reply To: Nopoo's post @ Jan 9 2019, 04:08 AM


$BBT.C Benchmark Botanics Appoints Agriculture Expert



#cannabis #stocks #marijuana #investing #MJ #microcaps

https://web.tmxmoney.com/article.php?newsid..._symbol=BBT:CNX




--------------------
Nopoo
 
Nopoo
post Posted: Jan 9 2019, 04:08 AM
  Quote Post


Posts: 147
Thanks: 6



$BBT.C Benchmark Botanics is a diversified multi-licensed cannabis producer focused on its three-way vertical business model, with sales and distribution into the medical, pharmaceutical, and recreational markets in Canada, and the EU. The Company’s business plan includes a strategy to become the first Canadian licensed producer to enter and sell nutraceutical medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics’ 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional 50,000 square foot facility. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research & development, genetics, CBD oil extraction and is progressing towards an EU-GMP certification.

As part of its expansion strategy the company’s plans to build up to 236,940 sq. ft. of growing space to produce 25,550 kg of cannabis per year and is building its second facility a 100% owned 4-acre (1,618 ha) Pitt Meadows Greenhouse Operations, in BC.

The Company has established several European Union partnerships including the rights to “The Bulldog” trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

Benchmark Botanics has entered into an agreement with Barcelona, Spain-based Green BCN Corp. (“BBG Projects”) for the development and production of new strains of cannabis plant varieties and their propagating material for sale and distribution. Benchmark Botanics has also established German commercial partnerships to import the Company’s products into Germany and distribute throughout Europe.

www.benchmarkbotanics.com




--------------------
Nopoo
 
blacksheep
post Posted: Dec 8 2018, 01:50 PM
  Quote Post


Posts: 6,791
Thanks: 2307


In Reply To: blacksheep's post @ Dec 7 2018, 02:41 PM

Extract from this US article https://mjbizdaily.com/aphria-cannabis-stock-plunging/. A number of ASX listed cannabis stocks have entered into arrangements with Canadian companies. Begs the question - how much due diligence have those ASX listed companies done on their partners?

QUOTE
2. Bigger than Aphria

The accusations could have broader implications for the industry and call into question just how much due diligence occurs as cannabis companies embark on their rapid expansions, said Andrew Kessner, an analyst with New York-based investment advising firm William O’Neil.

“Things have been moving so quickly in this space that a lot of companies have gotten a pass as far as what they’ve been spending their money on and why,” he said. “I think investors are starting to wise up and ask, ‘What’s really under the hood?’

“Are these executives really being good stewards of investor capital or are they inflating their company’s position to bring up valuations and do another round of funding?”

Damas agreed.

“It’s this sort of thing that could be the crack in the dike – so to speak,” he said. “It’s going to have ramifications for the whole industry.

“Other people are going to start taking a look at those assets that are far and away and wonder if they’re really worth what management is paying.”

3. Reassessing international plays

Aphria’s stock selloff could also signal just how critically investors view the international footprints of Canada’s larger cannabis producers, Kessner said.

“These companies have used the Canadian (capital) markets as a launching pad to raise money based on their plans to grow internationally,” he said.

“If that growth story – of being a global player – gets shot down, then their valuation begins to make no sense.”

Analysts at both GMP Securities and Bank of Nova Scotia moved their ratings for Aphria to “under review” after the short-seller report.

“We believe that management’s credibility may have been impacted by the allegations raised in this report,” GMP analysts wrote in a note to investors. “It is unclear at this point how the company will re-establish trust with investors.”


Might be a bit out of date, but - The Cannabis Index: A complete guide to cannabis stocks on the ASX - https://www.businessnewsaus.com.au/articles...on-the-asx.html




--------------------
The herd instinct among forecasters makes sheep look like independent thinkers. Edgar Fiedler

If the freedom of speech is taken away then dumb and silent we may be led, like sheep to the slaughter. George Washington
 
 


6 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING